Zinc Metallochaperones Reactivate Mutant p53 Using an ON/OFF Switch Mechanism: A New Paradigm in Cancer Therapeutics

PURPOSE: Zinc metallochaperones (ZMCs) are a new class of anti-cancer drugs that reactivate zinc deficient mutant p53 by raising and buffering intracellular zinc levels sufficiently to restore zinc binding. In vitro pharmacodynamics of ZMCs indicate that p53 mutant activity is ON by 4–6 hours and is...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Cancer Res
Hauptverfasser: Yu, Xin, Kogan, Samuel, Chen, Ying, Tsang, Ashley T., Withers, Tracy, Lin, Hongxia, Gilleran, John, Buckley, Brian, Moore, Dirk, Bertino, Joseph, Chan, Chang, Kimball, S. David, Loh, Stewart N., Carpizo, Darren R.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2018
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6139040/
https://ncbi.nlm.nih.gov/pubmed/29914895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0822
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge